Yahoo
Shanghai - Delayed Quote CNY

Kangmei Pharmaceutical Co., Ltd. (600518.SS)

1.3300 -0.0100 (-0.75%)
As of 1:05:15 PM GMT+8. Market Open.
Chart Range Bar
Loading chart for 600518.SS
  • Previous Close 1.3400
  • Open 1.3300
  • Bid 1.3400 x --
  • Ask 1.3500 x --
  • Day's Range 1.3300 - 1.3500
  • 52 Week Range 1.1600 - 2.1600
  • Volume 78,688,822
  • Avg. Volume 160,214,035
  • Market Cap (intraday) 18.392B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 134.00
  • EPS (TTM) 0.0100
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Aug 28, 2019
  • 1y Target Est --

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese herbal medicines in China. The company offers Chinese patent medicines, chemical medicines, and health food products. It also engages in the operation of Chinese medicinal materials markets; production and sale of medical devices; and operation of pharmaceutical logistics system. The company provides its products through medical institution resources, smart pharmacies, OTC retail, chain drug stores, direct sales, medical e-commerce, mobile medical care, etc. Kangmei Pharmaceutical Co., Ltd. was incorporated in 1997 and is based in Shenzhen, China.

www.kangmei.com.cn

5,492

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600518.SS
29.84%
SSE Composite Index (000001.SS)
8.99%

1-Year Return

600518.SS
35.58%
SSE Composite Index (000001.SS)
9.16%

3-Year Return

600518.SS
28.34%
SSE Composite Index (000001.SS)
19.18%

5-Year Return

600518.SS
65.55%
SSE Composite Index (000001.SS)
3.25%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY18
Revenue 8.47B
Earnings --
Profit Margin 0.00%

Q4

FY17

Q1

FY18

Q2

FY18

Q3

FY18

0
2B
4B
6B
8B
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.88%

  • Return on Assets (ttm)

    -1.14%

  • Return on Equity (ttm)

    1.27%

  • Revenue (ttm)

    4.82B

  • Net Income Avi to Common (ttm)

    90.65M

  • Diluted EPS (ttm)

    0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.36B

  • Total Debt/Equity (mrq)

    2.05%

  • Levered Free Cash Flow (ttm)

    -382.73M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: